Loading
Adding immunotherapy and olaparib to bevacizumab slowed progression but has not improved survival, and the regimen is not approved.
DUO-O, also ENGOT-ov46, trial NCT03737643 sponsored by AstraZeneca and reported at ASCO 2023, tested adding durvalumab and olaparib to chemotherapy plus bevacizumab in newly diagnosed non-BRCA-mutated advanced ovarian cancer, and found that the combination slowed progression but has not improved survival, so the regimen is not approved. It randomised 1,130 patients, met its primary progression-free survival endpoint in the non-BRCA population for the durvalumab plus olaparib arm, but the interim overall survival analysis published in Annals of Oncology in 2025 showed no survival signal. Whether any subgroup of ovarian cancer benefits from first-line checkpoint blockade remains the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Platinum-sensitive ovarian cancer, PARP, Olaparib, Bevacizumab.
Shares Platinum-sensitive ovarian cancer, Olaparib, AstraZeneca, Ovarian cancer.
Shares Caution: checkpoint inhibitors in first-line ovarian cancer, PD-L1, Bevacizumab, Ovarian cancer.
Shares Olaparib, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares PARP, Olaparib, Durvalumab, PD-L1.
Shares Platinum-sensitive ovarian cancer, Olaparib, AstraZeneca, Ovarian cancer.
Shares Durvalumab, Bevacizumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Olaparib, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.